Fasikl

Fasikl is a private, clinical-stage biotech company developing AI-driven neuromodulation therapies. The company has achieved a significant milestone with the FDA clearance of its first product, Felix, for essential tremor, validating its core neuro-AI platform. Built on over two decades of foundational R&D, Fasikl's technology includes advanced neural interfaces and AI models capable of single-fiber resolution recording and stimulation. The company is positioned to expand its platform into a broad pipeline of neurological indications and next-generation nerve-computer interfaces.

Proprietary neuro-AI platform combining high-fidelity neural interfaces (capable of single-fiber resolution recording and stimulation) with cloud-based AI models for real-time decoding and closed-loop modulation of neural signals.

Fasikl competes in the neuromodulation and digital therapeutics space. Direct competitors in essential tremor include Cala Health (non-invasive device). Broader competitors include large medtech companies with deep brain stimulation systems (Medtronic, Boston Scientific, Abbott) and a growing number of neurotech startups developing invasive and non-invasive brain-computer interfaces and adaptive neuromodulation therapies.